TD Asset Management Inc Has $8.21 Million Stock Holdings in Dyne Therapeutics, Inc. $DYN

TD Asset Management Inc raised its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 1,959.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 419,756 shares of the company’s stock after purchasing an additional 399,374 shares during the period. TD Asset Management Inc’s holdings in Dyne Therapeutics were worth $8,210,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Creative Planning boosted its holdings in Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after purchasing an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Dyne Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after buying an additional 1,440 shares in the last quarter. Caxton Associates LLP raised its position in shares of Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock valued at $158,000 after buying an additional 1,627 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Dyne Therapeutics by 9.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock valued at $315,000 after buying an additional 2,108 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at approximately $51,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Trading Up 6.6%

DYN opened at $17.92 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The company’s 50 day moving average price is $18.26 and its two-hundred day moving average price is $18.22. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -5.57 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the firm earned ($1.05) earnings per share. As a group, research analysts predict that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 287,956 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total value of $5,666,974.08. Following the completion of the transaction, the director directly owned 11,663 shares in the company, valued at approximately $229,527.84. This represents a 96.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have purchased 9,000 shares of company stock valued at $156,800 and have sold 1,559,462 shares valued at $29,814,746. Company insiders own 9.46% of the company’s stock.

Analyst Ratings Changes

DYN has been the topic of several research reports. Morgan Stanley decreased their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. HC Wainwright decreased their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.